Toll Free: 1-888-928-9744
Published: Jun, 2014 | Pages:
32 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Spherix Incorporated - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Spherix Incorporated - Product Pipeline Review - 2014', provides an overview of the Spherix Incorporated's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Spherix Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Spherix Incorporated including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Spherix Incorporated's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Spherix Incorporated's pipeline products Reasons to buy - Evaluate Spherix Incorporated's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Spherix Incorporated in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Spherix Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Spherix Incorporated and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Spherix Incorporated - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Spherix Incorporated and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Spherix Incorporated Snapshot 5 Spherix Incorporated Overview 5 Key Information 5 Key Facts 5 Spherix Incorporated - Research and Development Overview 6 Key Therapeutic Areas 6 Spherix Incorporated - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Spherix Incorporated - Pipeline Products Glance 12 Spherix Incorporated - Clinical Stage Pipeline Products 12 Phase I Products/Combination Treatment Modalities 12 Spherix Incorporated - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Spherix Incorporated - Drug Profiles 14 SPX-10624258 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 (SPX-106 + D-tagatose) 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 SPX-100 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 SPX-7233801 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 SPX-8522876 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 SPX-8818309 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 SPX-8818440 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Spherix Incorporated - Pipeline Analysis 22 Spherix Incorporated - Pipeline Products by Target 22 Spherix Incorporated - Pipeline Products by Molecule Type 23 Spherix Incorporated - Pipeline Products by Mechanism of Action 24 Spherix Incorporated - Recent Pipeline Updates 25 Spherix Incorporated - Company Statement 26 Spherix Incorporated - Locations And Subsidiaries 30 Head Office 30 Other Locations & Subsidiaries 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 32 Disclaimer 32
List of Tables Spherix Incorporated, Key Information 5 Spherix Incorporated, Key Facts 5 Spherix Incorporated - Pipeline by Indication, 2014 8 Spherix Incorporated - Pipeline by Stage of Development, 2014 9 Spherix Incorporated - Monotherapy Products in Pipeline, 2014 10 Spherix Incorporated - Combination Treatment Modalities in Pipeline, 2014 11 Spherix Incorporated - Phase I, 2014 12 Spherix Incorporated - Preclinical, 2014 13 Spherix Incorporated - Pipeline by Target, 2014 22 Spherix Incorporated - Pipeline by Molecule Type, 2014 23 Spherix Incorporated - Pipeline Products by Mechanism of Action, 2014 24 Spherix Incorporated - Recent Pipeline Updates, 2014 25 Spherix Incorporated, Subsidiaries 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.